Quantcast
Home > Quotes > MNLO

Menlo Therapeutics Inc. Common Stock (MNLO) Quote & Summary Data

MNLO 
$8
*  
0.19
2.43%
Get MNLO Alerts
*Delayed - data as of Mar. 18, 2019  -  Find a broker to begin trading MNLO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MNLO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
22
Today's High / Low
$ 8.15 / $ 7.74
Share Volume
239,114
50 Day Avg. Daily Volume
82,712
Previous Close
$ 7.81
52 Week High / Low
$ 38.8239 / $ 3.74
Market Cap
186,065,472
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.40
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.66

Intraday Chart

Shares Traded

Share Volume:
239,114
50 Day Avg. Daily Volume:
82,712

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.40

Trading Range

The current last sale of $8 is 113.90% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.15 $ 38.8239
 Low: $ 7.74 $ 3.74

Company Description (as filed with the SEC)

We are a late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions such as prurigo nodularis, psoriasis and chronic pruritus of unknown origin, or CPUO. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1-R, given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus. More than 80 million patients in the United States are affected by chronic pruritus associated with various conditions. Chronic pruritus is defined as pruritus lasting longer than six weeks. Pruritus is the primary complaint among patients with prurigo nodularis, psoriasis, and CPUO, often significantly impacting their quality of life. Current therapies, however, do not adequately control pruritus in many of these patients.  ... More ...  



Risk Grade

Where does MNLO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 7.85
Open Date:
Mar. 18, 2019
Close Price:
$ 8
Close Date:
Mar. 18, 2019


Consensus Recommendation

Analyst Info